SynthesisScientific reports2021
Efficacy and safety of liver support devices in acute and hyperacute liver failure: a systematic review and network meta-analysis.
Synthesis in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Liver support systems for adults with acute liver failure.The Cochrane database of systematic reviews · 2026Pooled it
- Artificial Liver Support Systems in Acute Liver Failure and Acute-on-Chronic Liver Failure: Systematic Review and Meta-Analysis.Critical care explorations · 2025Pooled it
- Impact of extracorporeal circuits on systemic drug levels - a scoping review.Journal of anesthesia, analgesia and critical care · 2026Review
- Combined application of double plasma molecular adsorption system treatment, plasma exchange, and continuous veno-venous hemofiltration to rescue an adult patient with acute liver failure induced by accidental acute severe thinner intoxication: a case report.Journal of medical case reports · 2026Article
- Impacts of hemoperfusion combined with continuous renal replacement therapy on renal function and immune function in patients with acute renal failure caused by poisoning.Frontiers in medicine · 2026Article
- Tissue-engineered liver using 3D-printed silk fibroin scaffolds loaded with stem cells for the treatment of acute liver injury.Regenerative biomaterials · 2025Article
- Implantable 3D printed hydrogels with intrinsic channels for liver tissue engineering.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Overview of acute liver failure in India.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Review
- Viral hepatitis-induced acute liver failure.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Review
- The Use and Potential Benefits of N-Acetylcysteine in Non-Acetaminophen Acute Liver Failure: An Etiology-Based Review.Biomedicines · 2024Review
- Hemoadsorption Therapy for Critically Ill Patients with Acute Liver Dysfunction: A Meta-Analysis and Systematic Review.Biomedicines · 2023Review
- Intensive care management of acute-on-chronic liver failure.Intensive care medicine · 2023Review
- Artificial Liver Support with CytoSorb and MARS in Liver Failure: A Retrospective Propensity Matched Analysis.Journal of clinical medicine · 2023Article
- [Acute Liver Failure: Current Updates and Management].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Review
- The Influence of Interdisciplinary Work towards Advancing Knowledge on Human Liver Physiology.Cells · 2022Review
- Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts.Intensive care medicine · 2022Review
- Management of Acute Liver Failure: Update 2022.Seminars in liver disease · 2022Article
- Extracorporeal Liver Support: An Updated Review of Mechanisms and Current Literature.Journal of community hospital internal medicine perspectives · 2022Review
- Mesenchymal Stromal/Stem Cells and Their Extracellular Vesicles Application in Acute and Chronic Inflammatory Liver Diseases: Emphasizing on the Anti-Fibrotic and Immunomodulatory Mechanisms.Frontiers in immunology · 2022Review
- Hemoadsorption in 'Liver Indication'-Analysis of 109 Patients' Data from the CytoSorb International Registry.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute liver failure (ALF) is a potentially life-threatening condition. Liver support therapies can be applied as a bridging-to-transplantation or bridging-to-recovery; however, results of clinical trials are controversial. Our aim was to compare liver support systems in acute and hyperacute liver failure with network meta-analysis. After systematic search, randomized controlled trials (RCT) comparing liver support therapies in adults with acute or hyperacute liver failure were included. In-hospital mortality was the primary outcome, the secondary outcomes were hepatic encephalopathy and mortality-by-aetiology. A Bayesian-method was used to perform network meta-analysis and calculate surface under the cumulative ranking curve (SUCRA) values to rank interventions. Eleven RCTs were included. BioLogic-DT and molecular adsorbent recirculating system (MARS) resulted in the lowest mortality (SUCRAs: 76% and 73%, respectively). In non-paracetamol-poisoned patients, BioLogic-DT, charcoal hemoperfusion and MARS may be equally efficient regarding mortality (SUCRAs: 53%, 52% and 52%, respectively). Considering hepatic encephalopathy, extracorporeal liver assist device (ELAD) may be the most effective option (SUCRA: 78%). However, in pairwise meta-analysis, there were no statistically significant differences between the interventions in the outcomes. In conclusion, MARS therapy seems to be the best available option in reducing mortality. Further research is needed on currently available and new therapeutic modalities. (CRD42020160133).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.